The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Coagulation Factor VIII Market Research Report 2025
Synopsis
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
The global Human Coagulation Factor VIII market was valued at US$ 10230 million in 2023 and is anticipated to reach US$ 15770 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.
Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.
This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VIII, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VIII.
Report Scope
The Human Coagulation Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Bottles) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Coagulation Factor VIII market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Coagulation Factor VIII manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Coagulation Factor VIII in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
The global Human Coagulation Factor VIII market was valued at US$ 10230 million in 2023 and is anticipated to reach US$ 15770 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.
Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.
This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VIII, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VIII.
Report Scope
The Human Coagulation Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Bottles) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Coagulation Factor VIII market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Coagulation Factor VIII manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Coagulation Factor VIII in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Coagulation Factor VIII Market Overview
1.1 Product Overview and Scope of Human Coagulation Factor VIII
1.2 Human Coagulation Factor VIII Segment by Type
1.2.1 Global Human Coagulation Factor VIII Market Value Comparison by Type (2024-2030)
1.2.2 Recombinant Factor VIII
1.2.3 Plasma-derived Factor VIII
1.3 Human Coagulation Factor VIII Segment by Application
1.3.1 Global Human Coagulation Factor VIII Market Value by Application: (2024-2030)
1.3.2 Hemophilia A
1.3.3 Spontanous / Trauma
1.3.4 Surgical
1.3.5 Other
1.4 Global Human Coagulation Factor VIII Market Size Estimates and Forecasts
1.4.1 Global Human Coagulation Factor VIII Revenue 2019-2030
1.4.2 Global Human Coagulation Factor VIII Sales 2019-2030
1.4.3 Global Human Coagulation Factor VIII Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Coagulation Factor VIII Market Competition by Manufacturers
2.1 Global Human Coagulation Factor VIII Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Coagulation Factor VIII Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Coagulation Factor VIII Average Price by Manufacturers (2019-2024)
2.4 Global Human Coagulation Factor VIII Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Coagulation Factor VIII, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Coagulation Factor VIII, Product Type & Application
2.7 Human Coagulation Factor VIII Market Competitive Situation and Trends
2.7.1 Human Coagulation Factor VIII Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Coagulation Factor VIII Players Market Share by Revenue
2.7.3 Global Human Coagulation Factor VIII Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Coagulation Factor VIII Retrospective Market Scenario by Region
3.1 Global Human Coagulation Factor VIII Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Coagulation Factor VIII Global Human Coagulation Factor VIII Sales by Region: 2019-2030
3.2.1 Global Human Coagulation Factor VIII Sales by Region: 2019-2024
3.2.2 Global Human Coagulation Factor VIII Sales by Region: 2025-2030
3.3 Global Human Coagulation Factor VIII Global Human Coagulation Factor VIII Revenue by Region: 2019-2030
3.3.1 Global Human Coagulation Factor VIII Revenue by Region: 2019-2024
3.3.2 Global Human Coagulation Factor VIII Revenue by Region: 2025-2030
3.4 North America Human Coagulation Factor VIII Market Facts & Figures by Country
3.4.1 North America Human Coagulation Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Coagulation Factor VIII Sales by Country (2019-2030)
3.4.3 North America Human Coagulation Factor VIII Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Coagulation Factor VIII Market Facts & Figures by Country
3.5.1 Europe Human Coagulation Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Coagulation Factor VIII Sales by Country (2019-2030)
3.5.3 Europe Human Coagulation Factor VIII Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Coagulation Factor VIII Market Facts & Figures by Country
3.6.1 Asia Pacific Human Coagulation Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Coagulation Factor VIII Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Coagulation Factor VIII Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Coagulation Factor VIII Market Facts & Figures by Country
3.7.1 Latin America Human Coagulation Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Coagulation Factor VIII Sales by Country (2019-2030)
3.7.3 Latin America Human Coagulation Factor VIII Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Coagulation Factor VIII Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Coagulation Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Coagulation Factor VIII Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Coagulation Factor VIII Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Coagulation Factor VIII Sales by Type (2019-2030)
4.1.1 Global Human Coagulation Factor VIII Sales by Type (2019-2024)
4.1.2 Global Human Coagulation Factor VIII Sales by Type (2025-2030)
4.1.3 Global Human Coagulation Factor VIII Sales Market Share by Type (2019-2030)
4.2 Global Human Coagulation Factor VIII Revenue by Type (2019-2030)
4.2.1 Global Human Coagulation Factor VIII Revenue by Type (2019-2024)
4.2.2 Global Human Coagulation Factor VIII Revenue by Type (2025-2030)
4.2.3 Global Human Coagulation Factor VIII Revenue Market Share by Type (2019-2030)
4.3 Global Human Coagulation Factor VIII Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Coagulation Factor VIII Sales by Application (2019-2030)
5.1.1 Global Human Coagulation Factor VIII Sales by Application (2019-2024)
5.1.2 Global Human Coagulation Factor VIII Sales by Application (2025-2030)
5.1.3 Global Human Coagulation Factor VIII Sales Market Share by Application (2019-2030)
5.2 Global Human Coagulation Factor VIII Revenue by Application (2019-2030)
5.2.1 Global Human Coagulation Factor VIII Revenue by Application (2019-2024)
5.2.2 Global Human Coagulation Factor VIII Revenue by Application (2025-2030)
5.2.3 Global Human Coagulation Factor VIII Revenue Market Share by Application (2019-2030)
5.3 Global Human Coagulation Factor VIII Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Shire (Baxter)
6.1.1 Shire (Baxter) Corporation Information
6.1.2 Shire (Baxter) Description and Business Overview
6.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Shire (Baxter) Human Coagulation Factor VIII Product Portfolio
6.1.5 Shire (Baxter) Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer Human Coagulation Factor VIII Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 CSL
6.3.1 CSL Corporation Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSL Human Coagulation Factor VIII Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Human Coagulation Factor VIII Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Corporation Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Grifols Human Coagulation Factor VIII Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 Biogen
6.6.1 Biogen Corporation Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Biogen Human Coagulation Factor VIII Product Portfolio
6.6.5 Biogen Recent Developments/Updates
6.7 Octapharma
6.6.1 Octapharma Corporation Information
6.6.2 Octapharma Description and Business Overview
6.6.3 Octapharma Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Octapharma Human Coagulation Factor VIII Product Portfolio
6.7.5 Octapharma Recent Developments/Updates
6.8 NovoNordisk
6.8.1 NovoNordisk Corporation Information
6.8.2 NovoNordisk Description and Business Overview
6.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.8.4 NovoNordisk Human Coagulation Factor VIII Product Portfolio
6.8.5 NovoNordisk Recent Developments/Updates
6.9 Greencross
6.9.1 Greencross Corporation Information
6.9.2 Greencross Description and Business Overview
6.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Greencross Human Coagulation Factor VIII Product Portfolio
6.9.5 Greencross Recent Developments/Updates
6.10 Kedrion
6.10.1 Kedrion Corporation Information
6.10.2 Kedrion Description and Business Overview
6.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Kedrion Human Coagulation Factor VIII Product Portfolio
6.10.5 Kedrion Recent Developments/Updates
6.11 BPL
6.11.1 BPL Corporation Information
6.11.2 BPL Human Coagulation Factor VIII Description and Business Overview
6.11.3 BPL Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.11.4 BPL Human Coagulation Factor VIII Product Portfolio
6.11.5 BPL Recent Developments/Updates
6.12 Hualan Bio
6.12.1 Hualan Bio Corporation Information
6.12.2 Hualan Bio Human Coagulation Factor VIII Description and Business Overview
6.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Hualan Bio Human Coagulation Factor VIII Product Portfolio
6.12.5 Hualan Bio Recent Developments/Updates
6.13 RAAS
6.13.1 RAAS Corporation Information
6.13.2 RAAS Human Coagulation Factor VIII Description and Business Overview
6.13.3 RAAS Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.13.4 RAAS Human Coagulation Factor VIII Product Portfolio
6.13.5 RAAS Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Coagulation Factor VIII Industry Chain Analysis
7.2 Human Coagulation Factor VIII Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Coagulation Factor VIII Production Mode & Process
7.4 Human Coagulation Factor VIII Sales and Marketing
7.4.1 Human Coagulation Factor VIII Sales Channels
7.4.2 Human Coagulation Factor VIII Distributors
7.5 Human Coagulation Factor VIII Customers
8 Human Coagulation Factor VIII Market Dynamics
8.1 Human Coagulation Factor VIII Industry Trends
8.2 Human Coagulation Factor VIII Market Drivers
8.3 Human Coagulation Factor VIII Market Challenges
8.4 Human Coagulation Factor VIII Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
